GlaxoSmithKline and Pfizer announce innovative agreement to create a new world-leading, specialist HIV company

  • Creates a new focused HIV business with the independence and sustainability to deliver significant improvements in treatment, access and shareholder value
  • Renews focus on HIV with industry-leading pipeline to deliver more new HIV treatments
  • Equity split of 85% GSK and 15% Pfizer


Clicca per visualizzare il comunicato stampa